Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical’s Rencofilstat to Treat Alcohol-Related Liver Disease
EDISON, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that its research collaborators from London’s Institute of Hepatology will present new findings on the Company’s cyclophilin inhibitor, rencofilstat, in an awarded oral presentation at the 2022 joint meeting of the International Society for Biomedical Research on Alcoholism (ISBRA) and European Society for Biomedical Research on Alcoholism (ESBRA), taking place September 17-20, 2022 in Cracow, Poland.
Related news for (HEPA)
- Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
- MoBot alert highlights: NASDAQ: LION, NASDAQ: HEPA, NASDAQ: EHTH, NASDAQ: DEVS, NASDAQ: PRCH (05/07/25 02:00 PM)
- Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
- Today’s Top Performers: MoBot’s Market Review 05/07/25 08:00 AM
- 24/7 Market News Snapshot 07 May, 2025 – Hepion Pharmaceuticals, Inc. Common Stock (NASDAQ:HEPA)